[1]

Ramamoorthy S, Cidlowski JA. 2016. Corticosteroids: mechanisms of action in health and disease. Rheumatic Diseases Clinics of North America 42:15−31,vii

doi: 10.1016/j.rdc.2015.08.002
[2]

Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, et al. 2021. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Delivery and Translational Research 11:866−93

doi: 10.1007/s13346-020-00843-z
[3]

Armaly MF. 1965. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Investigative Ophthalmology 4:187−97
[4]

Armaly MF, Becker B. 1965. Intraocular pressure response to topical corticosteroids. Federation Proceedings 24:1274−78
[5]

Teo BHK, Au Eong JTW, Au Eong KG. 2023. Steroid-induced glaucoma: an avoidable cause of irreversible blindness. BMJ Case Reports 16(9):e254709

doi: 10.1136/bcr-2023-254709
[6]

Lacau S, Marin A, Bitrian E. 2025. Steroid-induced ocular hypertension in children: a review on risk factors. Journal of Ocular Pharmacology and Therapeutics 41:305−13

doi: 10.1089/jop.2025.0024
[7]

Armaly MF. 1963. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Archives of Ophthalmology 70:492−99

doi: 10.1001/archopht.1963.00960050494011
[8]

Becker B, Mills DW. 1963. Corticosteroids and intraocular pressure. Archives of Ophthalmology 70:500−7

doi: 10.1001/archopht.1963.00960050502012
[9]

Podos SM, Becker B, Ross Morton W. 1966. High myopia and primary open-angle glaucoma. American Journal of Ophthalmology 62:1038−43

doi: 10.1016/0002-9394(66)92551-7
[10]

Spaeth GL. 1967. Traumatic hyphema, angle recession, dexamethasone hypertension, and glaucoma. Archives of Ophthalmology 78:714−21

doi: 10.1001/archopht.1967.00980030716005
[11]

Gaston H, Absolon MJ, Thurtle OA, Sattar MA. 1983. Steroid responsiveness in connective tissue diseases. British Journal of Ophthalmology 67:487−90

doi: 10.1136/bjo.67.7.487
[12]

Becker B, Bresnick G, Chevrette L, Kolker AE, Oaks MC, et al. 1966. Intraocular pressure and its response to topical corticosteroids in diabetes. Archives of Ophthalmology 76:477−83

doi: 10.1001/archopht.1966.03850010479003
[13]

Biedner BZ, David R, Grudsky A, Sachs U. 1980. Intraocular pressure response to corticosteroids in children. British Journal of Ophthalmology 64:430−31

doi: 10.1136/bjo.64.6.430
[14]

Kinoshita S, Kuwayama Y, Ohji M, Ohmi E. 1991. Marked intraocular pressure response to instillation of corticosteroids in children. American Journal of Ophthalmology 112:450−54

doi: 10.1016/S0002-9394(14)76256-7
[15]

Lam DS, Kwok AK, Chew S. 1997. Accelerated ocular hypertensive response to topical steroids in children. British Journal of Ophthalmology 81:422−23

doi: 10.1136/bjo.81.5.421d
[16]

Hutcheson KA. 2007. Steroid-induced glaucoma in an infant. Journal of AAPOS 11:522−23

doi: 10.1016/j.jaapos.2007.03.008
[17]

Roberti G, Oddone F, Agnifili L, Katsanos A, Michelessi M, et al. 2020. Steroid-induced glaucoma: epidemiology, pathophysiology, and clinical management. Survey of Ophthalmology 65:458−72

doi: 10.1016/j.survophthal.2020.01.002
[18]

Chinese Pediatric Society, Chinese Medical Association. 2012. 中国儿童青少年代谢综合征定义和防治建议 [The definition of metabolic syndrome and prophylaxis and treatment proposal in Chinese children and adolescents]. Chinese Journal of Pediatrics 50:420−2

doi: 10.3760/cma.j.issn.0578-1310.2012.06.005
[19]

Zhao Y, Wang L, Xue B, Wang Y. 2017. Associations between general and central obesity and hypertension among children: The Childhood Obesity Study in China Mega-Cities. Scientific Reports 7:16895

doi: 10.1038/s41598-017-16819-y
[20]

Lee SW, Jin KH, Lee SC, Cho BS, Park SS. 2010. Cataract and glaucoma in Korean children with chronic glomerulonephritis receiving systemic corticosteroid treatment. Acta Ophthalmologica 88:e344−e345

doi: 10.1111/j.1755-3768.2009.01816.x
[21]

Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, et al. 2009. Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases 68:1119−24

doi: 10.1136/ard.2008.092163
[22]

Gupta S, Shah P, Grewal S, Chaurasia AK, Gupta V. 2015. Steroid-induced glaucoma and childhood blindness. British Journal of Ophthalmology 99:1454−56

doi: 10.1136/bjophthalmol-2014-306557
[23]

Senthil S, Thakur M, Rao HL, Mohamed A, Jonnadula GB, et al. 2020. Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis. British Journal of Ophthalmology 104:265−69

doi: 10.1136/bjophthalmol-2019-313988
[24]

Takano F, Ueda K, Yamada-Nakanishi Y, Nakamura M. 2025. Risk factors of pediatric steroid-induced ocular hypertension. Graefe’s Archive for Clinical and Experimental Ophthalmology 263:867−72

doi: 10.1007/s00417-024-06669-6
[25]

Kim SH, Kim SE, Choi MH, Park MJ. 2021. Altered glucocorticoid metabolism in girls with central obesity. Molecular and Cellular Endocrinology 527:111225

doi: 10.1016/j.mce.2021.111225
[26]

Krag S, Larsen D, Albertsen BK, Glerup M. 2021. Risk of ocular hypertension in children treated with systemic glucocorticoid. Acta Ophthalmologica 99:e1430−e1434

doi: 10.1111/aos.14820
[27]

Wang JC, Gray NE, Kuo T, Harris CA. 2012. Regulation of triglyceride metabolism by glucocorticoid receptor. Cell & Bioscience 2:19

doi: 10.1186/2045-3701-2-19
[28]

Lee MJ, Pramyothin P, Karastergiou K, Fried SK. 2014. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842:473−81

doi: 10.1016/j.bbadis.2013.05.029
[29]

Lengton R, Iyer AM, van der Valk ES, Hoogeveen EK, Meijer OC, et al. 2022. Variation in glucocorticoid sensitivity and the relation with obesity. Obesity Reviews 23:e13401

doi: 10.1111/obr.13401